- Home
- THCH vs NTRB Comparison
THCH vs NTRB Comparison
Compare THCH & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THCH
- NTRB
- Stock Information
- Founded
- THCH 2018
- NTRB 2016
- Country
- THCH China
- NTRB United States
- Employees
- THCH N/A
- NTRB N/A
- Industry
- THCH Blank Checks
- NTRB Industrial Specialties
- Sector
- THCH Finance
- NTRB Health Care
- Exchange
- THCH Nasdaq
- NTRB Nasdaq
- Market Cap
- THCH 84.8M
- NTRB 82.3M
- IPO Year
- THCH N/A
- NTRB N/A
- Fundamental
- Price
- THCH $2.60
- NTRB $6.57
- Analyst Decision
- THCH
- NTRB Buy
- Analyst Count
- THCH 0
- NTRB 1
- Target Price
- THCH N/A
- NTRB $13.00
- AVG Volume (30 Days)
- THCH 11.8K
- NTRB 201.7K
- Earning Date
- THCH 08-28-2025
- NTRB 09-02-2025
- Dividend Yield
- THCH N/A
- NTRB N/A
- EPS Growth
- THCH N/A
- NTRB N/A
- EPS
- THCH N/A
- NTRB N/A
- Revenue
- THCH $187,384,526.00
- NTRB $2,398,437.00
- Revenue This Year
- THCH N/A
- NTRB $560.75
- Revenue Next Year
- THCH N/A
- NTRB $588.39
- P/E Ratio
- THCH N/A
- NTRB N/A
- Revenue Growth
- THCH N/A
- NTRB 18.92
- 52 Week Low
- THCH $1.95
- NTRB $2.98
- 52 Week High
- THCH $5.15
- NTRB $9.42
- Technical
- Relative Strength Index (RSI)
- THCH 40.71
- NTRB 38.02
- Support Level
- THCH $2.49
- NTRB $6.55
- Resistance Level
- THCH $2.90
- NTRB $7.78
- Average True Range (ATR)
- THCH 0.26
- NTRB 0.60
- MACD
- THCH -0.02
- NTRB -0.11
- Stochastic Oscillator
- THCH 65.66
- NTRB 20.09
About THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.